肺癌患者血清β-防御素浓度升高。
Elevated serum beta-defensins concentrations in patients with lung cancer.
作者信息
Arimura Yasuji, Ashitani Jun-ichi, Yanagi Shigehisa, Tokojima Masatoshi, Abe Koh, Mukae Hiroshi, Nakazato Masamitsu
机构信息
Third Department of Internal Medicine, Miyazaki Medical College, Kiyotake 5200, Miyazaki 889-1692, Japan.
出版信息
Anticancer Res. 2004 Nov-Dec;24(6):4051-7.
BACKGROUND
Beta-defensins (HBDs) are expressed in lung epithelial cells and act as antimicrobial agents. Most lung cancers that originate from pulmonary epithelial cells may produce HBDs.
MATERIALS AND METHODS
We measured serum HBD-1 and HBD-2 levels in healthy subjects (HS), patients with lung cancer and patients with pneumonia by radioimmunoassay.
RESULTS
Serum HBD-1 levels were higher in patients with lung cancer than HS and patients with pneumonia. Serum HBD-2 levels were higher in patients with lung cancer than HS. When cut-off values for positive HBD-1 were set at mean + 2SD of HS, the sensitivity and specificity of HBD-1 for the whole group of patients with lung cancer were 76.4 and 94.0%, respectively, and the proportion of patients with HBD-1-positive lung cancer and clinical stage I was 69.2%.
CONCLUSION
Serum HBDs levels were high in patients with lung cancer and the serum HBD-1 level could be used as an auxiliary diagnostic tool for lung cancer.
背景
β-防御素（HBDs）在肺上皮细胞中表达并作为抗菌剂发挥作用。大多数起源于肺上皮细胞的肺癌可能会产生HBDs。
材料与方法
我们通过放射免疫测定法测量了健康受试者（HS）、肺癌患者和肺炎患者血清中的HBD-1和HBD-2水平。
结果
肺癌患者血清HBD-1水平高于健康受试者和肺炎患者。肺癌患者血清HBD-2水平高于健康受试者。当将HBD-1阳性的临界值设定为健康受试者均值 + 2标准差时，HBD-1对肺癌患者全组的敏感性和特异性分别为76.4%和94.0%，HBD-1阳性肺癌患者且临床分期为I期的比例为69.2%。
结论
肺癌患者血清HBDs水平较高，血清HBD-1水平可作为肺癌的辅助诊断工具。
Zotero 插件